Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry.

AIMS To investigate the influence of polymorphisms in CYP2C9, VKORC1, CYP4F2 and F2 genes on warfarin dose-response and develop a model including genetic and non-genetic factors for warfarin dose prediction needed for each patient. METHODS A total of 279 patients of European ancestry on warfarin medication were investigated. Genotypes for -1639G>A, 1173C>T, and 3730G>A SNPs in the VKORC1 gene, CYP2C9*2 and CYP2C9*3, 1347C>T in the CYP4F2 gene and 494C>T in the F2 gene were determined by allelic discrimination with Taqman 5'-nuclease assays. RESULTS The CYP2C9*2 and CYP2C9*3 polymorphisms in the CYP2C9 gene, -1639G>A and 1173C>T in the VKORC1 gene and 494C>T in the F2 gene are responsible for lower anticoagulant doses. In contrast, 1347C>T in the CYP4F2 gene and 3730G>A in the VKORC1 gene are responsible for higher doses of warfarin. An algorithm including genetic, biological and pharmacological factors that explains 63.3% of warfarin dose variation was developed. CONCLUSION The model suggested has one of the highest coefficients of determination among those described in the literature.

[1]  D. Balding.  A tutorial on statistical methods for population association studies , 2006, Nature Reviews Genetics.

[2]  M. Margaglione,et al.  Polymorphisms in factor II and factor VII genes modulate oral anticoagulation with warfarin. , 2004, Haematologica.

[3]  Howard L McLeod,et al.  Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin , 2003, Thrombosis and Haemostasis.

[4]  T. Baglin,et al.  Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. , 2000 .

[5]  V. Dolžan,et al.  The influence of sequence variations in factor VII, γ-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement , 2006, Thrombosis and Haemostasis.

[6]  I. Ieiri,et al.  Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity. , 2003, Blood.

[7]  G. Suarez-Kurtz,et al.  Impact of CYP4F2 rs2108622 on the Stable Warfarin Dose in an Admixed Patient Cohort , 2010, Clinical pharmacology and therapeutics.

[8]  L. Rohde,et al.  Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols. , 2004, The American journal of medicine.

[9]  R. Barrack,et al.  Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients , 2008, Journal of thrombosis and haemostasis : JTH.

[10]  M. Charng,et al.  A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. , 2005, Human molecular genetics.

[11]  A. Hofman,et al.  Patients with an ApoE ϵ4 allele require lower doses of coumarin anticoagulants , 2005, Pharmacogenetics and genomics.

[12]  M. Loriot,et al.  Genetic Factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) Are Predictor Variables for Warfarin Response in Very Elderly, Frail Inpatients , 2010, Clinical pharmacology and therapeutics.

[13]  M. Margaglione,et al.  Genetic Modulation of Oral Anticoagulation with Warfarin , 2000, Thrombosis and Haemostasis.

[14]  Shun Higuchi,et al.  Warfarin-dosing algorithm based on a population pharmacokinetic/pharmacodynamic model combined with Bayesian forecasting. , 2009, Pharmacogenomics.

[15]  H. Halkin,et al.  Combined genetic profiles of components and regulators of the vitamin K-dependent γ-carboxylation system affect individual sensitivity to warfarin , 2006, Thrombosis and Haemostasis.

[16]  F. Marín,et al.  The genetic interaction between VKORC1 c1173t and calumenin a29809g modulates the anticoagulant response of acenocoumarol , 2007, Journal of thrombosis and haemostasis : JTH.

[17]  F. Kamali,et al.  The effect of simvastatin co-medication on warfarin anticoagulation response and dose requirements , 2003, Thrombosis and Haemostasis.

[18]  M. Margaglione,et al.  A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. , 2005, Blood.

[19]  J. Hirsh,et al.  Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. , 2001, Chest.

[20]  M. Rieder,et al.  Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin , 2008, Clinical pharmacology and therapeutics.

[21]  Panos Deloukas,et al.  The largest prospective warfarin-treated cohort supports genetic forecasting. , 2009, Blood.

[22]  E. Dias-Neto,et al.  Pharmacogenetics of Warfarin: Development of a Dosing Algorithm for Brazilian Patients , 2008, Clinical pharmacology and therapeutics.

[23]  P. Deloukas,et al.  Gamma-glutamyl carboxylase (GGCX) microsatellite and warfarin dosing. , 2005, Blood.

[24]  Y. Kokubo,et al.  Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. , 2007, Thrombosis research.

[25]  Munir Pirmohamed,et al.  Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. , 2010, Blood.

[26]  Hee-Jin Kim,et al.  Factors affecting the interindividual variability of warfarin dose requirement in adult Korean patients. , 2007, Pharmacogenomics.

[27]  E. Molden,et al.  Probable Warfarin–Simvastatin Interaction , 2007, The Annals of pharmacotherapy.

[28]  J. Long,et al.  An E-M algorithm and testing strategy for multiple-locus haplotypes. , 1995, American journal of human genetics.

[29]  Brian F. Gage,et al.  Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues , 2008, Journal of Thrombosis and Thrombolysis.

[30]  E. Mesquita,et al.  CYP2C9 genotypes and the quality of anticoagulation control with warfarin therapy among Brazilian patients , 2007, European Journal of Clinical Pharmacology.

[31]  R. Kim,et al.  CYP2C9 allelic variants: ethnic distribution and functional significance. , 2002, Advanced drug delivery reviews.

[32]  Peter Wood,et al.  The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. , 2005, Blood.

[33]  Y. Turpaz,et al.  CYP4F2 genetic variant alters required warfarin dose. , 2008, Blood.

[34]  R. Altman,et al.  Estimation of the warfarin dose with clinical and pharmacogenetic data. , 2009, The New England journal of medicine.

[35]  H. Halkin,et al.  Interindividual variability in sensitivity to warfarin‐Nature or nurture? , 2001, Clinical pharmacology and therapeutics.

[36]  Zhenya Shen,et al.  Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients , 2007, European Journal of Clinical Pharmacology.

[37]  F. Kamali,et al.  Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin , 2004, Clinical pharmacology and therapeutics.

[38]  Nicole Soranzo,et al.  A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose , 2009, PLoS genetics.

[39]  Yusheng Zhu,et al.  Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes. , 2007, Clinical chemistry.

[40]  Placido Bramanti,et al.  CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. , 2009, Pharmacogenomics.

[41]  D. Sane,et al.  The inhibitory effect of calumenin on the vitamin K-dependent gamma-carboxylation system. Characterization of the system in normal and warfarin-resistant rats. , 2004, The Journal of biological chemistry.

[42]  H. Halkin,et al.  Common Genetic Variants of Microsomal Epoxide Hydrolase Affect Warfarin Dose Requirements Beyond the Effect of Cytochrome P450 2C9 , 2005, Clinical pharmacology and therapeutics.